RESUMEN
Chimpanzees were injected with OKT3 and two other anti-CD3 antibodies, OKT3D and OKT3E. Both of the new antibodies were of the mouse IgG2b isotype. Administration of the antibodies was identical to the clinical regimen used for OKT3 in humans: 5 mg i.v., daily for 10 consecutive days. All animals were monitored for fever during administration of the antibodies, and blood samples were taken throughout the treatment period for monitoring the effects of the antibodies on peripheral lymphocyte subsets and the appearance of circulating cytokines. OKT3 produced similar clinical effects to those observed in humans; fever (2/3), as well as elevations in cytokines were observed. As in humans, peripheral T cells were cleared with the first dose and remained absent or modulated of their T cell receptor molecules throughout treatment. OKT3D, IgG2b also produced fevers (2/3) and elevations of cytokines. Although it also cleared circulating T cells with the first dose and T cell counts remained low throughout treatment, remaining circulating T cells were coated with administered antibody and were able to reexpress the CD3 antigen. OKT3E, IgG2b produced no temperature elevations and no elevations in cytokines. Although it cleared the circulation of T cells with the first does, cells reappeared during treatment, modulated of their CD3 antigens or coated with the administered antibody. All three antibodies raised antimouse antibodies, and OKT3 and OKT3D also produced blocking antiidiotype antibodies. OKT3E treatment did not result in anti-OKT3E blocking antibodies.
Asunto(s)
Anticuerpos Antiidiotipos/inmunología , Anticuerpos Monoclonales/efectos adversos , Antígenos de Diferenciación de Linfocitos T/inmunología , Pan troglodytes/inmunología , Receptores de Antígenos de Linfocitos T/inmunología , Animales , Anticuerpos Antiidiotipos/biosíntesis , Anticuerpos Monoclonales/inmunología , Complejo CD3 , Epítopos/inmunología , Inmunoglobulina G/inmunología , Linfocitos/inmunología , Linfocinas/metabolismo , RatonesAsunto(s)
Aminopiridinas/farmacología , Proteínas Quinasas Dependientes de Calcio-Calmodulina/antagonistas & inhibidores , Inhibidores Enzimáticos/farmacología , Proteínas Quinasas Activadas por Mitógenos , Pirroles/farmacología , Animales , Artritis Experimental/patología , Humanos , Técnicas In Vitro , Interleucina-1/antagonistas & inhibidores , Lipopolisacáridos , Masculino , Ratones , Ratones Endogámicos BALB C , Monocitos/efectos de los fármacos , Monocitos/metabolismo , Ratas , Ratas Endogámicas Lew , Linfocitos T/efectos de los fármacos , Linfocitos T/metabolismo , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Proteínas Quinasas p38 Activadas por MitógenosRESUMEN
These studies deal with the expression of a functional IL 2 receptor on activated primary human B cells. Antibody against the receptor (alpha-TAC) reacted with 25 to 65% activated B cells, inhibited B cell proliferation by 50% and inhibited B cell secretion of Ig by greater than 90%. These effects were shown to be independent of contaminating T lymphocytes. Anti-TAC immunoprecipitated a molecule of identical size (65,000 daltons) from T and B lymphocytes; B cells were also shown to actively synthesize the IL 2 receptor. The chymotryptic peptide chromatograms of TAC antigen from T and B cells show these molecules to be indistinguishable.
Asunto(s)
Linfocitos B/metabolismo , Activación de Linfocitos , Receptores Inmunológicos/análisis , Anticuerpos Monoclonales/fisiología , Reacciones Antígeno-Anticuerpo , Antígenos de Superficie/análisis , Antígenos de Superficie/inmunología , Linfocitos B/inmunología , Unión Competitiva , Quimotripsina/farmacología , Proteínas del Sistema Complemento/fisiología , Técnica de Placa Hemolítica , Humanos , Interleucina-2/fisiología , Fragmentos de Péptidos/aislamiento & purificación , Pruebas de Precipitina , Receptores de Interleucina-2 , Miembro 7 de la Superfamilia de Receptores de Factores de Necrosis TumoralRESUMEN
Tumor necrosis factor-alpha (TNF-alpha), a cytokine secreted by activated monocytes/macrophages and T lymphocytes, has been implicated in several disease states, including rheumatoid arthritis, inflammatory bowel disease, septic shock, and osteoporosis. Monocyte/macrophage production of TNF-alpha is dependent on the mitogen-activated protein kinase p38. RWJ 67657 (4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol -2-yl]-3-butyn-1-ol) inhibited the release of TNF-alpha by lipopolysaccharide (a monocyte stimulus)-treated human peripheral blood mononuclear cells with an IC(50) of 3 nM, as well as the release of TNF-alpha from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B (a T cell stimulus), with an IC(50) value of 13 nM. This compound was approximately 10-fold more potent than the literature standard p38 kinase inhibitor SB 203580 in all p38 dependent in vitro systems tested. RWJ 67657 inhibited the enzymatic activity of recombinant p38alpha and beta, but not gamma or delta, in vitro and had no significant activity against a variety of other enzymes. In contrast, SB 203580 significantly inhibited the tyrosine kinases p56 lck and c-src (IC(50) = 5 microM). RWJ 67657 did not inhibit T cell production of interleukin-2 or interferon-gamma and did not inhibit T cell proliferation in response to mitogens. RWJ 67657 inhibited TNF-alpha production in lipopolysaccharide-injected mice (87% inhibition at 50 mg/kg) and in rats (91% inhibition at 25 mg/kg) after oral administration. Based on these favorable biological properties, RWJ 67657 may have use as a treatment for inflammatory diseases.